This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).

开始日期2023-08-01

申办/合作机构

NYU Langone Health

NCT05368402 / Terminated临床2期

Randomized, Placebo-controlled, Double-blinded, 2-parallel Arm, Clinical Trial Evaluating Ladarixin 400 mg Bid as Adjunctive Therapy to Improve Glycemic Control in Overweight Insulin-resistant Patients With Type 1 Diabetes.

Primary objective: To determine whether oral ladarixin versus placebo adjunctive therapy improves glycemic control in overweight, insulin resistant (IR) adult subjects with type 1 diabetes (T1D).
Secondary objectives: To ascertain the effect of ladarixin on glycemic variability as per CGM derived parameters. To determine the safety of oral ladarixin versus placebo adjunctive therapy in overweight, IR adult subjects with T1D.
Exploratory objectives (if site is able and deems appropriate to accommodate and conduct these objectives): To determine the effects on insulin sensitivity and circulating markers of inflammation (leukocytes and inflammatory cytokines). Glycemic variability by additional CGM parameters. eGDR and BMI assessments.

开始日期2022-07-27

申办/合作机构

Dompe Farmaceutici SpA

100 项与 Ladarixin Sodium 相关的临床结果

登录后查看更多信息

100 项与 Ladarixin Sodium 相关的转化医学

登录后查看更多信息

100 项与 Ladarixin Sodium 相关的专利（医药）

登录后查看更多信息

项与 Ladarixin Sodium 相关的文献（医药）

2024-10-15·Clinical Cancer Research

Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development

Article

作者: Brandolini, Laura ; Simon Nieto, Juan ; Foderaro, Simone ; De Schrijver, Celine ; Pérez-Boza, Jennifer ; Pegtel, Dirk Michiel ; Sensoy, Hilal N. ; Baglio, Serena Rubina ; Giorgio, Cristina ; Dell’Aversana, Carmela ; Atmopawiro, Alisha ; Lagerweij, Tonny ; Mulders, Manon ; Gómez-Martín, Cristina ; Allegretti, Marcello ; van Weering, Jan R.T. ; Massaro, Crescenzo ; Bebelman, Maarten ; Savci-Heijink, Cemile Dilara ; Altucci, Lucia ; van de Donk, Niels W.C.J. ; Bosch, Leontien ; Neves Ferreira, Mafalda ; van Eijndhoven, Monique A.J.

AbstractPurpose:Therapy resistance is a major clinical hurdle in bone cancer treatment and seems to be largely driven by poorly understood microenvironmental factors. Recent evidence suggests a critical role for a unique subpopulation of mesenchymal stem cells with inflammatory features (iMSC), though their origin and function remained unexplored. We demonstrate that cancer-secreted extracellular vesicles (EV) trigger the development of iMSCs, which hinder therapy response in vivo, and set out to identify strategies to counteract their function.Experimental Design:The role of iMSCs in therapy resistance was evaluated in an orthotopic xenograft mouse model of osteosarcoma. EV-induced alterations of the MSC transcriptome were analyzed and compared with single-cell RNA sequencing data of biopsies from patients with osteosarcoma and multiple myeloma. Functional assays identified EV components driving iMSC development. We assessed the efficacy of clinical drugs in blocking iMSC-induced resistance in vivo.Results:We found that iMSCs are induced by interaction with cancer EVs and completely abrogate the antimetastatic effect of TGFβ signaling inhibition. Importantly, EV-induced iMSCs faithfully recapitulate the inflammatory single-cell RNA signature of stromal cells enriched in biopsies from patients with multiple myeloma and osteosarcoma. Mechanistically, cancer EVs act through two distinct mechanisms. EV-associated TGFβ induces IL6 production, whereas the EV-RNA cargo enhances TLR3-mediated chemokine production. We reveal that simultaneous blockade of downstream EV-activated pathways with ladarixin and tocilizumab disrupts metastasis formation and overcomes iMSC-induced resistance.Conclusions:Our observations establish iMSCs as major contributors to drug resistance, reveal EVs as triggers of iMSC development, and highlight a promising combination strategy to improve therapy response in patients with bone cancer.

2024-09-05·Cardiovascular research

Modulation of MMP9 and CXCR2/CXCL1/IL-8 axis in human abdominal aortic aneurysm tissues by ladarixin.

Article

作者: Chiesa, Roberto ; Ardita, Vincenzo ; Nicolo, Sabrina ; Aramini, Andrea ; Foglieni, Chiara ; De Filippis, Lidia ; Allegretti, Marcello ; Spartano, Lucia ; Lombardi, Maria ; Baccellieri, Domenico

2023-10-01·Diabetes/metabolism research and reviews

The therapeutic potential of an allosteric non-competitive CXCR1/2 antagonist for diabetic nephropathy.

Article

作者: Grasselli, Chiara ; D'Esposito, Vittoria ; Formisano, Pietro ; Pagni, Fabio ; Di Tolla, Michele Francesco ; Perego, Roberto ; Allegretti, Marcello ; Rocchio, Francesca ; Bombelli, Silvia ; De Filippis, Lidia ; Miscione, Martina Sara ; Novelli, Rubina ; L'Imperio, Vincenzo ; Ruffini, Pier Adelchi ; Aramini, Andrea

AIMSDiabetic nephropathy is a major consequence of inflammation developing in type 1 diabetes, with interleukin-8 (IL-8)-CXCR1/2 axis playing a key role in kidney disease progression. In this study, we investigated the therapeutic potential of a CXCR1/2 non-competitive allosteric antagonist (Ladarixin) in preventing high glucose-mediated injury in human podocytes and epithelial cells differentiated from renal stem/progenitor cells (RSC) cultured as nephrospheres.MATERIALS AND METHODSWe used human RSCs cultured as nephrospheres through a sphere-forming functional assay to investigate hyperglycemia-mediated effects on IL-8 signalling in human podocytes and tubular epithelial cells.RESULTSHigh glucose impairs RSC self-renewal, induces an increase in IL-8 transcript expression and protein secretion and induces DNA damage in RSC-differentiated podocytes, while exerting no effect on RSC-differentiated epithelial cells. Accordingly, the supernatant from epithelial cells or podocytes cultured in high glucose was able to differentially activate leucocyte-mediated secretion of pro-inflammatory cytokines, suggesting that the crosstalk between immune and non-immune cells may be involved in disease progression in vivo.CONCLUSIONSTreatment with Ladarixin during RSC differentiation prevented high glucose-mediated effects on podocytes and modulated either podocyte or epithelial cell-dependent leucocyte secretion of pro-inflammatory cytokines, suggesting CXCR1/2 antagonists as possible pharmacological approaches for the treatment of diabetic nephropathy.

项与 Ladarixin Sodium 相关的新闻（医药）

2023-07-11

·PRNewswire

Less than half of endocrinologists are impressed with Tzield's ability to delay T1D (MARKETVUE® REPORT)

Sanofi/formerly Provention's Tzield (teplizumab), a CD3 mAb, is the only FDA-approved disease-modifying therapy that delays progression of Stage 2 T1D in patients 8 years and older. However, less than half of U.S. clinicians are impressed with the drug's ability to delay T1D onset, according to findings from REACH Market Research. NEWTON, Mass., July 11, 2023 /PRNewswire/ -- Type 1 Diabetes (T1D) is a life-long autoimmune disease where the immune system destroys the insulin-producing islet cells in the pancreas until they no longer produce insulin. To date, insulin replacement therapy has been the backbone of T1D treatment but has a significant treatment burden on patients. Recently, clinical development appears to be shifting towards therapies that could delay the need for insulin and preserve beta cell function. To access REACH's MarketVue® Report on Type 1 Diabetes, visit or contact us at [email protected]. The launch of Tzield is an important milestone in T1D disease management in that patients in the pre-diabetic stage now have an option to delay T1D onset by ~2 years, thereby delaying insulin use. Further, the approval has increased interest and awareness around screening patients who may be at risk for the disease. While the approval of Tzield has created excitement amongst clinicians, the response to its efficacy and dosing is underwhelming; less than 30% of interviewed doctors reported that they found the dosing impressive, according to REACH Market Research 's MarketVue® assessment. Endocrinologist, U.S.: "What are the potential benefits of a drug like teplizumab in a person who has stage 2 diabetes? It is not a magical bullet, but it's a good start." The current T1D pipeline consists largely of insulin-based treatments with few therapies in development to delay T1D and insulin use in recent-onset patients, including: Sanofi's teplizumab label extension for patients 0-7 yrs and recent-onset T1D NIDDK's anti-thymocyte globulin and granulocyte colony-stimulating factor Diamyd Medical AB's Diamyd, an anti-IL5 mAb Dompe Farmaceutici S.p.A's ladarixin, an anti-IL-8, CXCR1 and CXCR2 inhibitor Novartis' iscalimab, an anti-CD40 mAb Endocrinologists interviewed by REACH are eager for preventative treatments that offer a longer time to T1D progression and more convenient dosing than Tzield. Meghana Pandit, REACH Analyst: "Tzield as a concept is viewed favorably by physicians, however, there are concerns around its dosing, and efficacy profile which is reported as marginal." About MarketVue® MarketVue® reports are a rare disease focused, fresh alternative to traditionally long and outdated market research reports. MarketVue® reports cover rare disease epidemiology and key market dynamics based on research from key opinion leader interviews, physician surveys, and secondary data. About REACH Market Research REACH is an independent pharmaceutical market research company focused on rare and niche diseases. With decades of experience in pharmaceutical market research and life sciences consulting, REACH fills an important gap in the market – accessible market research solutions for rare and niche diseases. SOURCE REACH Market Research

上市批准

2023-03-02

·PRNewswire

DelveInsight Evaluates a Robust Diabetes Pipeline as 200+ Influential Pharma Players to Set Foot in the Domain

The prevalence of diabetes has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Diabetes and the growing research and development activities to develop novel therapies to treat diabetes to drive the market. The companies developing the potential therapies in the last stage of development include Eli Lilly and Company, Daewoong Pharmaceutical, Janssen Biotech, and several others. LAS VEGAS, March 2, 2023 /PRNewswire/ -- DelveInsight's ' Diabetes Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the diabetes pipeline domain. Key Takeaways from the Diabetes Pipeline Report DelveInsight's diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for diabetes treatment. Key diabetes companies such as Daewoong Pharmaceutical, Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian, Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen, Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici S.p.A, ILTOO Pharma, Throne Biotechnologies, Oramed Pharmaceuticals, Janssen Research & Development, LLC, Jaguar Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR Therapeutics, Biora Therapeutics, Genprex, Inc., and others are evaluating new diabetes drugs to improve the treatment landscape. Promising diabetes pipeline therapies in various stages of development include Enavogliflozin, Golimumab, Dasiglucagon, ThermoStem, rGDF11, IMCY-0098, Insulin icodec, CagriSema, FDC Sema-OW GIP, SemaDapa FDC, ENT-001, AG019, JTT-662, AVT-001, AZD-0186, Cotadutide, LABP-111, VX-880, Encapsulated islet cell program, CPP-1X-T, REMD-477, AT-1501, LY 3209590, Orforglipron, LY3437943, Mazdutide, Peptide YY analogue agonist, GIPR agonist long acting, GIPR Agonist Long Acting II, LY 3493269, NNC0363-0845, Diamyd, ProTrans, VC-02, OPT101, Ladarixin, ILT-101, Stem Cell Educator Therapy, ORMD-0801, Golimumab, JAG301, SQZ TAC research program, VCTX 211, and others. In February 2023, Genprex, Inc. announced that data highlighting the potential of its gene therapy for Type 1 diabetes was being presented by its research collaborators at the University of Pittsburgh at the four-day International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023).These results were compelling as they demonstrated the potential for this gene therapy to create newly formed beta-like cells that can produce insulin. They also validated earlier studies of this approach in diabetic mouse models that showed restoration of normal blood glucose levels for several months. In February 2023, Provention Bio, Inc. announced the closing of the $35 million equity investment from Sanofi US under the previously announced Co-Promotion Agreement and Securities Purchase Agreement (the "Purchase Agreement").Pursuant to the Purchase Agreement, Sanofi purchased 2,712,497 shares of the Company's common stock, par value $0.0001 per share, at a price of $12.90 per share, representing a total investment of $35 million. In January 2023, iTolerance, Inc. announced it has entered into a Master Services Agreement (MSA) with the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine, for the advancement of its novel iTOL-100 platform technology as a potential cure for Type 1 Diabetes. In November 2022, Biocon Limited announced the signing of a semi-exclusive partnership agreement with Zentiva, a leading pharmaceutical company in Europe, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.Under the terms of this agreement, Biocon is responsible for the manufacturing and supply of Liraglutide to Zentiva for its commercialization across 30 countries in Europe. Biocon also retained the right to commercialize this product under its own brand in the region. In November 2022, The US Food and Drug Administration (FDA) approved Provention Bio's biologics license application (BLA) for Tzield (teplizumab-mzwv) to treat type 1 diabetes (T1D) patients. The anti-CD3-directed antibody Tzield aims to delay the onset of Stage 3 T1D in adults and children aged eight years and above who are currently with stage 2 T1D. Request a sample and discover the recent advances in diabetes drug treatment @ Diabetes Pipeline Report The diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage diabetes drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the diabetes clinical trial landscape. Diabetes Overview Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body does not use the insulin that is produced effectively. The vast majority of diabetes can be divided into two types: type 1 and type 2. Diabetes symptoms include polyuria, polydipsia, weight loss, sometimes accompanied by polyphagia and blurred vision. Chronic hyperglycemia may also cause growth impairment and susceptibility to certain infections. Diabetes long-term complications include retinopathy, which can lead to vision loss, nephropathy, which can lead to renal failure, peripheral neuropathy, which can lead to foot ulcers, amputations, and Charcot joints, and autonomic neuropathy, which can cause gastrointestinal, genitourinary, and cardiovascular symptoms. Diabetes is diagnosed through a thorough physical examination, medical history, and a battery of specialized tests. The A1C, or glycated hemoglobin test, is the primary test used to diagnose both type 1 and type 2 diabetes. Diabetes treatment typically consists of diet control, exercise, home blood glucose testing, oral medication, and insulin. Insulin is the primary treatment for type 1 diabetes, and people with type 2 diabetes can be treated with oral medications but may need insulin in some cases. Find out more about drugs for diabetes @ New Diabetes Drugs A snapshot of the Diabetes Pipeline Drugs mentioned in the report: Learn more about the emerging diabetes pipeline therapies @ Diabetes Clinical Trials Diabetes Therapeutics Assessment The diabetes pipeline report proffers an integral view of diabetes emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Diabetes Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Tumor necrosis factor alpha inhibitors, Glucagon receptor agonists, Cytotoxic T lymphocyte stimulants, Apoptosis inhibitors, Caspase inhibitors, Insulin-like growth factor binding protein inhibitors, Gene transference, Interleukin-10 expression modulators, CD40 antigen modulators Key Diabetes Companies: Daewoong Pharmaceutical, Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian, Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen, Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici S.p.A, ILTOO Pharma, Throne Biotechnologies, Oramed Pharmaceuticals, Janssen Research & Development, LLC, Jaguar Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR Therapeutics, Biora Therapeutics, Genprex, Inc., and others. Key Diabetes Pipeline Therapies: Enavogliflozin, Golimumab, Dasiglucagon, ThermoStem, rGDF11, IMCY-0098, Insulin icodec, CagriSema, FDC Sema-OW GIP, SemaDapa FDC, ENT-001, AG019, JTT-662, AVT-001, AZD-0186, Cotadutide, LABP-111, VX-880, Encapsulated islet cell program, CPP-1X-T, REMD-477, AT-1501, LY 3209590, Orforglipron, LY3437943, Mazdutide, Peptide YY analogue agonist, GIPR agonist long acting, GIPR Agonist Long Acting II, LY 3493269, NNC0363-0845, Diamyd, ProTrans, VC-02, OPT101, Ladarixin, ILT-101, Stem Cell Educator Therapy, ORMD-0801, Golimumab, JAG301, SQZ TAC research program, VCTX 211 and others. Dive deep into rich insights for new drugs for diabetes treatment; visit @ Diabetes Medications Table of Contents For further information on the diabetes pipeline therapeutics, reach out @ Diabetes Drug Treatment Related Reports Type 1 Diabetes Market Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Histogen , Novo Nordisk, Prevention Bio, among others. Type 1 Diabetes Epidemiology Forecast Type 1 Diabetes Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted type 1 diabetes epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Diabetes Market Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others. Type 2 Diabetes Market Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, AstraZeneca, Novartis, among others. Type 2 Diabetes Pipeline Type 2 Diabetes Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, Novartis, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Blogs Evolution in Diabetes Management Diabetes Management and Care Increasing Prevalence of Diabetes Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

并购引进/卖出

2021-02-11

·药融圈

40款新药出现研发进展，3款新药重磅来袭！多款新药研发阶段发生改变，涉及罗氏、君实、礼来、兆科等！

▲速抢免费参会名额 | 大湾区(广州)生物医药创新者峰会导语根据公开资料不完全统计，药融云为大家检测到了2021年1月29日至2021年2月5日的全球新药重大研发进展40条。其中涉及药物提交上市申请3条，临床重大进展37条，其中有1条获得特殊审批途径。跨国药企在国际上大展拳脚，国产药企也不遑多让。君实生物研发的etesevimab获“紧急使用授权”资格，为治疗新冠添砖加瓦。君实生物的股票也节节升高。“国产之光”CT-707进入临床三期，我国原研抗肿瘤药再添一大助力。数据来源：药融云全球药物研发数据库据统计，40款药物的治疗领域主要是肿瘤、神经系统、感染等。生物药生物药中nemolizumab提交上市申请； Etesevimab公布3期临床试验结果； 01 nemolizumab（奈莫利珠单抗）近日，罗氏研发（Galderma SA和Maruho Co Ltd合作研发）的nemolizumab提交上市申请，nemolizumab是一种抗白细胞介素31受体（IL-31R）的人源化单克隆抗体，用于治疗特应性皮炎、结节性痒疹，曾获“突破性疗法”资格认定。Nemolizumab可通过竞争性地阻断IL-31与其受体的结合来抑制IL-31的生物活性，阻断IL-31信号传导。IL-31是一种诱导瘙痒的细胞因子，其信号传导在结节性痒疹发病机制中起着关键作用。 Nemolizumab的III期临床试验共入组了215例日本13岁以上的中度至重度瘙痒患者，根据基线瘙痒视觉模拟量表(VAS)评分中位数为75.4分。研究中，患者以2:1的比例随机分配，接受每4周一次皮下注射nemolizumab或安慰剂治疗直至第16周（nemolizumab组，n=143；安慰剂组，n=72；）。该研究中，患者同时使用局部抗炎药。 02 etesevimab 2020年11月礼来递交Bamlanivimab+etesevimab联合治疗新型肺炎冠状病毒感染(COVID-19)的“紧急使用授权”申请，近日此申请获批。君实生物研发（礼来合作研发）的etesevimab是一种抑制COVID19刺突糖蛋白的人源化单克隆抗体，用于治疗新型肺炎冠状病毒感染(COVID-19)和病毒性肺炎。Etesevimab能特异性结合SARS-CoV-2表面刺突蛋白受体结构域，并能有效阻断病毒与宿主细胞表面ACE2受体的结合。将点突变引入人类IgG1抗体以减轻效应。 2020年5月4日，礼来与君实生物达成合作协议，以1000万美元预付款+2.44亿美元里程碑金额获得etesevimab大中华区外的全球权益。 2021年1月26日，礼来宣布，BLAZE-1研究的III期临床试验达到主要研究终点，Bamlanivimab 2800mg 和Etesevimab 2800mg联合治疗显著降低了近期被确诊为新型肺炎冠状病毒感染(COVID-19)高风险患者COVID-19相关住院和死亡事件（下称：“事件”）。在1035名患者中，双抗体联合治疗组事件发生率为2.1%（11例），安慰剂组事件发生率为7.0% （36例），表明事件发生风险降低了70% (p=0.0004)。研究中共有10例死亡，均发生在安慰剂组，Bamlanivimab和Etesevimab双抗体联合治疗组中无死亡事件。 Bamlanivimab和Etesevimab双抗体联合治疗组在所有关键次要终点方面也显示出统计学显著改善，为该疗法可降低病毒载量并加速症状缓解提供了有力的证据。 03 COVAC-2 萨斯喀彻温大学研发的治疗新型肺炎冠状病毒感染(COVID-19)的COVAC-2。 04 BIVV-020 赛诺菲研发的BIVV-020是一种补体C1s抑制剂，用于治疗慢性炎性脱髓鞘性多发性神经根神经病、冷凝集素病、血小板减少症。 2020年12月16日，赛诺菲向NMPA递交1类进口治疗用生物制品BIVV-020注射液的临床申请。 05 REGN-5668 再生元研发的双特异性抗体REGN-5668是一种黏蛋白16调节剂和T-细胞表面糖蛋白CD28刺激剂，用于治疗输卵管癌、转移性卵巢癌和腹膜肿瘤。 06 MT-1002 陕西麦科奥特科技有限公司研发的MT-1002是凝血因子IIa和糖蛋白IIb/IIIa拮抗剂，用于治疗急性冠状动脉综合征和血栓形成。 07 HB-201 HOOKIPA Pharma Inc研发的HB-201是一种人乳头瘤病毒E6和E7蛋白抑制剂，用于治疗腺癌、头颈部肿瘤、口腔肿瘤、咽喉部肿瘤、鳞状细胞癌和子宫颈癌。小分子治疗药小分子治疗药中阿达帕林+盐酸克林霉素、二甲亚砜提交上市申请； Ladarixin和CT-707进入临床三期； 01 阿达帕林+盐酸克林霉素李氏大药厂研发的维甲酸受体激动剂adapalene + clindamycin hydrochloride（阿达帕林+盐酸克林霉素）用于治疗痤疮。李氏大药厂的综合性基地之一兆科（广州）眼科药物有限公司于2021年2月2日向NMPA递交上市申请。阿达帕林盐酸克林霉素复方凝胶的关键Ⅲ期临床试验的主要数据表明，该研究已达到主要终点指标，证明阿达帕林盐酸克林霉素复方凝胶优于单独使用阿达帕林凝胶或克林霉素凝胶，具有高度统计差异（P<0.0001）。阿达帕林盐酸克林霉素复方凝胶的Ⅲ期多中心、随机、单盲、平行、阳性对照研究（NCT03615768）旨在评估阿达帕林盐酸克林霉素复方凝胶治疗中度寻常型痤疮的疗效性和安全性。先前Ⅱ期临床研究结果表明，0.1% 阿达帕林+1%克林霉素是治疗寻常型痤疮的最佳组合，并在Ⅲ期临床研究中用作实验组。该复方凝胶通过结合使用两种具有不同作用机理的药物及增加克林霉素的吸收来产生协同效应，从而减少使用抗生素以避免产生细菌耐药性。 02 二甲亚砜杏林制药研发的dimethyl sulfoxide（二甲亚砜）用于治疗间质性膀胱炎，获“孤儿药”资格认定。 03 ladarixin Dompe Group研发的ladarixin是一种CXC趋化因子受体1和2、白介素8受体拮抗剂，用于治疗1型糖尿病，获得“儿科用药研究计划”。 Ladarixin的临床三期试验是一项随机、多中心、双盲、安慰剂试验，入组患者为有较低残余β细胞功能的青少年和成人新发1型糖尿病患者，主要目的是评估通过抑制CXCL-8（IL-8）的生物学活性来维持β细胞功能的有效性。目前，该试验在美国的临床试验点已启动患者招募，计划在2021年上半年开始研究。欧洲试验点的招募预计将持续到2022年。 ladarixin 的3期临床试验的启动遵循了2期临床试验（NCT02814838）的结果，在2期临床研究中，两个研究组之间未检测到临床相关的安全性观察结果。此外，在2期临床研究中，抑制CXCL-8（IL-8）的新方法，在新发1型糖尿病患者中显示出保存胰腺β细胞和延缓疾病进展的良好效果。研究中，ladarixin的耐受性良好。 04 CT-707 北京赛林泰研发的CT-707是一种间变性淋巴瘤激酶受体和黏着斑激酶2抑制剂，用于治疗非小细胞肺癌。CT-707是我国自主研发、具有完全只是产权的1类创新药，是全新结构的二代ALK抑制剂。结语辞旧迎新跨年前后，多款药物提交上市申请和进入临床三期，不泛有国产原研新药。随着国产创新企业在资本、政策的推动下迅速崛起，国产药企融入世界，我国成为新药主流市场亦不远矣。版权声明：本文转自药融云，如不希望被转载的媒体或个人可与我们联系，我们将立即删除【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。点分享点点赞点在看

抗体合作孤儿药特殊审批突破性疗法

100 项与 Ladarixin Sodium 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16212

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰岛素抵抗	临床1期	意大利	Dompe Farmaceutici SpA	2022-07-27
大疱性类天疱疮	临床1期	意大利	Dompe Farmaceutici SpA	2012-02-20
大疱性类天疱疮	临床1期	德国	Dompe Farmaceutici SpA	2012-02-20
1型糖尿病	药物发现	意大利	Dompé Pharmaceutici Spa	2020-12-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02814838 (MEX0114, CTgov)	临床2期	1型糖尿病	76	Ladarixin (Ladarixin)	積淵壓網鬱淵網顧餘蓋(鹹膚簾觸齋廠製鏇顧鏇) = 選願鑰簾糧顧衊積願鏇觸艱製膚範餘齋醖襯夢 (膚獵餘網衊簾範餘憲糧, 築襯憲遞壓齋範願構膚 ~ 簾鑰蓋獵齋簾壓範憲窪) 更多	-	2021-01-12
				Placebo (Placebo)	積淵壓網鬱淵網顧餘蓋(鹹膚簾觸齋廠製鏇顧鏇) = 築糧遞構構艱蓋範廠鏇觸艱製膚範餘齋醖襯夢 (膚獵餘網衊簾範餘憲糧, 蓋鹽夢網築積願壓齋壓 ~ 獵襯膚築廠鑰襯鏇鏇鹹) 更多
NCT02814838 (ADA2020)	临床2期	1型糖尿病	76	Ladarixin 400 mg BID	(獵選窪網糧壓鹹鬱獵築) = 鬱餘蓋蓋構衊壓範鹹鑰鑰築廠艱獵廠壓鹽蓋艱 (獵鹽壓選餘範鹽蓋製顧 )	-	2020-06-01
				Placebo	(獵選窪網糧壓鹹鬱獵築) = 選積繭壓壓鏇簾網網窪鑰築廠艱獵廠壓鹽蓋艱 (獵鹽壓選餘範鹽蓋製顧 )